Tuberculosis in Australia: bacteriologically confirmed cases and drug resistance, 2001
DOI:
https://doi.org/10.33321/cdi.2003.27.41Keywords:
Mycobacterium tuberculosis, Mycobacterium bovis, laboratory diagnosis, tuberculosis, drug resistanceAbstract
The Australian Mycobacterium Reference Laboratory Network collected and analysed laboratory data on new cases of disease caused by Mycobacterium tuberculosis complex in the year 2001. A total of 771 cases were identified, representing an annual reporting rate of 4.0 cases of laboratory-confirmed tuberculosis per 100,000 population. The predominant specimen type was sputum, (n=369) and a further 111 were collected at bronchoscopy. Smears were positive for 214 of 369 (58.0%) sputum and 42 of 111 (37.8%) bronchoscopy specimens respectively. Seven children (male n=5, female n=2) under 10 years of age had bacteriologically confirmed tuberculosis. A total of 69 isolates (8.9%), comprising 67 M. tuberculosis, one M. africanum, and one M. bovis, were resistant to at least one of the anti-tuberculosis agents. Excluding the M. bovis isolate, 61 of 64 (93.5%) were classified as having initial resistance, three had acquired resistance, and no data were available on the presence or absence of previous treatment for four patients. Resistance to at least isoniazid and/or rifampicin was noted for 67 isolates (8.7%), with resistance to both isoniazid and rifampicin (i.e. defined as multidrug-resistant disease) observed in 12 (1.6%) isolates. All of the multidrug-resistant isolates were M. tuberculosis, 10 were from the respiratory tract. The country of birth was known for 63 of 68 (92.6%) patients with a drug-resistant strain of M. tuberculosis or M. africanum; five were Australian-born and 58 (92.1%) had migrated from a total of 22 countries. One hundred seven respiratory specimens had a nucleic acid amplification testing performed; 89 of 90 (98.9%) smear positives were nucleic acid amplification testing positive, whilst only 13 of 17 (76.5%) smear negative specimens were nucleic acid amplification testing positive. The 2001 laboratory data reveals a stable incidence rate and level of drug resistance in isolates from Australian patients with tuberculosis. Commun Dis Intell 2003;27:173-180.
Downloads
References
National TB Advisory Committee. Tuberculosis in Australia, 1998. Commun Dis Intell 2001;25:1-8.
Dawson S, Anargyros P, Blacklock Z, Chew W, Dagnia H, Gow B, et al. Tuberculosis in Australia: an analysis of cases identified in reference laboratories in 1986-88. Pathology 1991;23:130-134.
Dawson D. Tuberculosis in Australia; bacteriologically confirmed cases and drug resistance, 1997. Commun Dis Intell 1999;23:349-353.
Royal College of Pathologists of Australasia. Quality Assurance Programs Final Report 2002 D4.
Communicable Diseases Network Australia. National Strategic Plan for TB Control in Australia Beyond 2000. July 2002.
Australian Bureau of Statistics. Australian Demographic Statistics, June Quarter 2001.
World Health Organization. Guidelines for surveillance of drug resistance in tuberculosis. WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance. 2001 WHO/CDS/TB/2001. Geneva: World Health Organization.
Lumb R, Bastian I, Dawson D, Gilpin C, Haverkort F, James G, Sievers A. Tuberculosis in Australia: bacteriologically confirmed cases and drug resistance, 2000. Commun Dis Intell 2002;26:226-233.
Dawson D. Tuberculosis in Australia: bacteriologically confirmed cases and drug resistance, 1998 and 1999. Commun Dis Intell 2001;25:261-265.
Dawson D, Cheah DF, Chew F, Haverkort F, Lumb R, Sievers AS. Tuberculosis in Australia, 1989-1992. Bacteriologically confirmed cases and drug resistance. Med J Aust 1995;162:287-290.
Miller M, Lin M, Spencer J, National TB Advisory Committee. Tuberculosis notifications in Australia, 2001. Commun Dis Intell 2002;26:525-526.
Al-Kaassimi FA, Azhar M, Al-Majed S, Al-Wazzan AD, Al-Hajjaj MS, Malibary T. Diagnostic role of fiberoptic bronchoscopy in tuberculosis in the presence of typical x-ray pictures and adequate sputum. Tubercle 1991;72:145-148.
McWilliams T, Wells AU, Harrison AC, Lindstrom S, Cameron RJ, Foskin E. Induced sputum and bronchoscopy in the diagnosis of pulmonary tuberculosis. Thorax 2002;57:1010-1014.
Telenti A, Imboden P, Marchesi F, Lowrie D, Cole S, Colston MJ, et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 1993;341:647-650.
De Beenhouwer H, Lhiang Z, Jannes G, Mijs W, Machtelinckx L, Rossau R, et al. Rapid detection of rifampicin resistance in sputum and biopsy specimens from tuberculosis patients by PCR and line probe assay. Tuberc Lung Dis 1994;76:425-430.
Garrino M, Glupczynski Y, Degraux J, Ninet, H, Delmee M. Evaluation of the Abbott LCx Mycobacterium tuberculosis assay for direct detection of Mycobacterium tuberculosis complex in human samples. J Clin Microbiol 1999;37:229-232.
Moore DF, Curry JI. Detection and identification of Mycobacterium tuberculosis directly from sputum sediments by ligase chain reaction. J Clin Microbiol 1998;36:1028-1031.
Lumb R, Davies K, Dawson D, Ginn R, Gottlieb T, Kershaw, C, et al. Multicenter evaluation of the Abbott LCx Mycobacterium tuberculosis ligase chain reaction assay. J Clin Microbiol 1999;37:3102-3107.
Ausina V, Gamboa F, Gazapo E, Manterola JM, Lonca J, Matas L, et al. Evaluation of the semi-automated Abbott LCx Mycobacterium tuberculosis assay for direct detection of Mycobacterium tuberculosis in respiratory specimens. J Clin Microbiol 1997;35:1996-2002.
Rish JA, Eisenach KD, Cave MD, Reddy MV, Gangadharam PRJ, Bates JH. Polymerase chain reaction detection of Mycobacterium tuberculosis in formalin-fixed tissue. Am J Respir Crit Care Med 1996;153:1419-1423.
Downloads
Published
How to Cite
License
Copyright (c) 2003 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
